Your browser is no longer supported. Please, upgrade your browser.
ZYNE Zynerba Pharmaceuticals, Inc. daily Stock Chart
Zynerba Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.88 Insider Own1.10% Shs Outstand18.01M Perf Week-0.76%
Market Cap94.01M Forward P/E- EPS next Y-2.46 Insider Trans2.59% Shs Float14.72M Perf Month33.16%
Income-40.20M PEG- EPS next Q-0.65 Inst Own19.10% Short Float15.63% Perf Quarter-2.79%
Sales- P/S- EPS this Y3.90% Inst Trans3.68% Short Ratio3.40 Perf Half Y-16.75%
Book/sh3.85 P/B1.36 EPS next Y13.70% ROA-63.30% Target Price16.40 Perf Year-54.57%
Cash/sh3.68 P/C1.42 EPS next 5Y- ROE-74.80% 52W Range2.75 - 12.50 Perf YTD75.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.74% Beta4.99
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low82.99% ATR0.39
Employees22 Current Ratio8.00 Sales Q/Q- Oper. Margin- RSI (14)53.96 Volatility4.62% 8.40%
OptionableYes Debt/Eq0.00 EPS Q/Q25.80% Profit Margin- Rel Volume1.14 Prev Close5.22
ShortableYes LT Debt/Eq0.00 EarningsMar 11 BMO Payout- Avg Volume677.13K Price5.03
Recom- SMA203.30% SMA5017.28% SMA200-28.79% Volume599,461 Change-3.60%
Feb-01-18Resumed H.C. Wainwright Buy $23
Jan-29-18Initiated Ladenburg Thalmann Buy $25.50
Jan-26-18Initiated Seaport Global Securities Buy $16
Oct-02-17Upgrade Cantor Fitzgerald Neutral → Overweight $4 → $17
Sep-29-17Upgrade Piper Jaffray Neutral → Overweight
Aug-15-17Upgrade ROTH Capital Neutral → Buy
Aug-15-17Downgrade Oppenheimer Outperform → Perform
Aug-15-17Downgrade Jefferies Buy → Hold
Aug-08-17Downgrade ROTH Capital Buy → Neutral
Aug-08-17Downgrade H.C. Wainwright Buy → Neutral $7
Aug-07-17Downgrade Piper Jaffray Overweight → Neutral
Aug-07-17Downgrade Maxim Group Buy → Hold
Aug-07-17Downgrade Cantor Fitzgerald Overweight → Neutral $28 → $4
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Feb-24-17Initiated Maxim Group Buy $32
Dec-22-16Initiated Cantor Fitzgerald Overweight $28
Dec-06-16Resumed Jefferies Buy
Oct-07-16Initiated H.C. Wainwright Buy $22
Nov-12-15Reiterated Oppenheimer Outperform $40 → $34
Sep-08-15Initiated Oppenheimer Outperform $40
Feb-13-19 11:45AM  Healthcare Investment Opportunities You Can't Miss ACCESSWIRE
Feb-11-19 09:55AM  Biotech Stocks To Watch ACCESSWIRE
Feb-08-19 09:30AM  Has Zynerba Pharmaceuticals (ZYNE) Outpaced Other Medical Stocks This Year? Zacks
Feb-07-19 11:44AM  Zynerba Stock Is Marijuana-Adjacent Play Worth a Look InvestorPlace
Feb-05-19 10:34AM  Top Marijuana Stocks on the NASDAQ Investopedia -6.69%
10:00AM  Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference GlobeNewswire
Feb-04-19 03:41PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3 Zacks +5.87%
11:00AM  Cannabis & Biotech Stocks Starting to Rally in 2019 ACCESSWIRE
Feb-01-19 08:30AM  Biotechs to Put on Your Watchlist ACCESSWIRE +10.50%
Jan-30-19 08:00AM  Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals ACCESSWIRE
08:00AM  Biotechs You Need to Radar Now ACCESSWIRE
Jan-29-19 02:30PM  These 4 Healthcare Stocks Healthy With Potential Opportunities ACCESSWIRE +25.26%
12:56PM  Zynerba Pharmaceuticals News: Why ZYNE Stock Is Soaring Today InvestorPlace
08:30AM  Wall Street's Favorite Cannabis Stock Benzinga
Jan-22-19 08:45AM  SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors PR Newswire
Jan-07-19 09:00AM  Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock Zacks
Jan-04-19 05:11PM  Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine? Investor's Business Daily +8.99%
Dec-19-18 09:15AM  Zynerba Gives Clinical Update, Lifelong Impact Of ZYN002 Market Exclusive
Dec-13-18 07:56AM  The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen Benzinga -7.23%
Dec-12-18 05:30PM  Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002 GlobeNewswire
06:31AM  When Will Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Become Profitable? Simply Wall St.
Nov-23-18 07:40AM  Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-21-18 11:30AM  Opioid Alternatives Could Make Investors Major Gains ACCESSWIRE
Nov-20-18 08:00AM  Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-13-18 02:19PM  Sell-Side Analysts See Upside Potential In Zynerba Benzinga -5.12%
Nov-08-18 10:00AM  Zynerba: 3Q Earnings Snapshot Associated Press +6.15%
06:45AM  Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Nov-01-18 10:30AM  Reading Filings to Predict Future Events ACCESSWIRE +9.89%
Oct-26-18 02:00PM  Short Sellers Are Making Huge Profits In Cannabis Stocks Benzinga
Oct-23-18 10:09AM  Medical Cannabis Stocks Vs. Recreational Cannabis Stocks: Which Ones Should You Invest In? Investopedia
Oct-22-18 08:37AM  Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options Zacks -7.66%
Oct-11-18 10:47AM  Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum GlobeNewswire
Oct-03-18 07:30PM  Beverage Giants Buying Into The Cannabis Boom
Oct-01-18 10:32AM  2 Marijuana Biotechs to Watch InvestorPlace
09:45AM  The Hottest CBD Stocks ACCESSWIRE
Sep-26-18 09:00AM  Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-21-18 03:32PM  Cantor Fitzgerald's 7 Buys For 7 Biotechs Benzinga +5.74%
Sep-20-18 08:55AM  Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock? Zacks
Sep-19-18 10:30AM  CBD Stocks Set to Explode ACCESSWIRE +7.82%
08:11AM  What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment? Simply Wall St.
Aug-31-18 08:30AM  Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-30-18 12:42PM  Zynerba Pharmaceuticals Continues Its 3-Day Rally InvestorPlace
Aug-13-18 11:24PM  Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-09-18 08:51AM  The Worst-Performing Marijuana Stocks in July Motley Fool
Aug-02-18 06:57AM  Zynerba: 2Q Earnings Snapshot Associated Press -10.75%
06:50AM  Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Aug-01-18 08:46AM  Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference GlobeNewswire
Jul-31-18 07:30AM  Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update GlobeNewswire
Jul-25-18 07:30AM  This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up ACCESSWIRE
Jul-24-18 12:33PM  Market Roasts Shares of Zynerba Pharmaceuticals InvestorPlace
Jul-20-18 12:53PM  Main Line synthetic cannabinoid developer seeking $32.5M from stock sale American City Business Journals -24.09%
11:18AM  Tilrays IPO is creating a buzz, but dont overspend on marijuana stocks MarketWatch
09:10AM  Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
07:53AM  Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2 Benzinga
Jul-19-18 04:01PM  Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Jul-12-18 07:30AM  Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome GlobeNewswire
Jul-09-18 06:55AM  Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome GlobeNewswire
Jul-08-18 09:35AM  Zynerba stock rebounds after selloff driven by failed cannabis-based skin patch trial MarketWatch
Jul-05-18 03:37PM  HC Wainwright Unfazed By Zynerba Ending ZYN001: Drug 'Wasn't In Our Numbers' Benzinga
09:09AM  Zynerba Redirects Resources After ZYN001 Study Fails To Meet Top-Line Results Benzinga
07:43AM  Zynerba shares slide 17% after trial of cannabis-based skin patch fails to meet goals MarketWatch
07:30AM  Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study GlobeNewswire
Jun-26-18 03:24PM  FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight
Jun-25-18 01:06PM  GW Pharma's Epidiolex Becomes First Cannabis-Based FDA-Approved Drug Benzinga -9.33%
May-31-18 08:00AM  Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-27-18 07:30PM  The Tech Revolutionizing The Billion Dollar Marijuana Business
May-18-18 10:48PM  Pot Stock Winners of the Week Investopedia
May-11-18 09:15AM  Interested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Heres How It Performed Recently Simply Wall St. +5.49%
May-08-18 08:11AM  Zynerba: 1Q Earnings Snapshot Associated Press -13.13%
07:30AM  Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Apr-25-18 07:00AM  Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN) GlobeNewswire
Apr-23-18 07:00AM  Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018 GlobeNewswire
Apr-22-18 01:46PM  What Do Analysts Think About Zynerba Pharmaceuticals Incs (NASDAQ:ZYNE) Earnings Trend? Simply Wall St.
Apr-17-18 12:20PM  Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes Investor's Business Daily
Apr-16-18 07:00AM  Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors GlobeNewswire
Apr-13-18 09:20AM  Is Cannabis The Answer To Seizures? These Biotechs Say Yes Investor's Business Daily
Apr-10-18 07:00AM  Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE) GlobeNewswire
Apr-03-18 02:15PM  Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98? Simply Wall St. +14.16%
Mar-26-18 07:00AM  Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model GlobeNewswire
Mar-22-18 06:45AM  Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN) GlobeNewswire
Mar-15-18 07:26PM  Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Simply Wall St.
Mar-14-18 09:00AM  Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-13-18 08:20AM  Todays Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals ACCESSWIRE
Mar-12-18 06:53AM  Zynerba reports 4Q loss Associated Press +15.21%
06:45AM  Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights GlobeNewswire
Mar-07-18 07:10AM  Wired News Zynerba Pharma Held Positive Discussion Meeting with FDA for its ZYN002 Development Strategy ACCESSWIRE
Mar-05-18 02:50PM  Main Line pharma company plans key study of Fragile X syndrome therapy American City Business Journals
06:45AM  Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing GlobeNewswire
Jan-31-18 01:39PM  Look Beyond Pharma to Invest in Marijuana Industry Insider Monkey
Jan-29-18 02:05PM  Can Zynerba Pharma Shares Really Still Double in These High Times? 24/7 Wall St. +6.05%
Jan-03-18 04:30PM  Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update GlobeNewswire
Dec-23-17 10:31AM  Can This Beaten-Down Marijuana Stock Roar Back in 2018? Motley Fool
Dec-17-17 07:30PM  Canadas Cannabis Market Could Be About To Explode
Dec-13-17 03:24PM  Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE): Does -3.8% EPS Drop In A Year Reflect The Long-Term Trend? Simply Wall St.
Dec-05-17 08:20AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals ACCESSWIRE
Dec-04-17 12:32PM  Zynerba Pharmaceuticals Volatile After Epilepsy Study Results Benzinga -8.30%
Dec-03-17 12:01PM  Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire
Nov-21-17 09:00AM  Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire +5.43%
Nov-20-17 05:15PM  Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)? Simply Wall St.
Nov-14-17 07:34AM  Zynerba reports 3Q loss Associated Press +11.07%
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butler John P.DirectorAug 22Buy6.435,00032,1535,000Aug 22 04:39 PM
ANIDO ARMANDOChairman & Chief Exec. OfficerAug 06Buy5.9615,00089,423352,512Aug 07 04:32 PM
Sebree Terri BPresidentAug 06Buy5.793,80022,013182,546Aug 07 04:29 PM
Hanlon Suzanne M.Sec, VP & General CounselAug 06Buy5.803,80022,04843,693Aug 07 04:30 PM
Fickenscher James EChief Financial OfficerAug 06Buy5.978,51850,84220,718Aug 07 04:28 PM
RAPP MICHAEL10% OwnerMay 30Buy10.455,88561,4981,500,000May 31 09:26 AM
RAPP MICHAEL10% OwnerMay 02Buy10.4615,000156,9451,494,115May 02 05:38 PM
RAPP MICHAEL10% OwnerMar 22Buy9.2810,00092,7901,479,115Mar 23 09:30 AM